Faricimab lacks proof of added benefit over comparator therapies for macular edema

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion.

Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023 – Biotech Investments

Fresenius SE & Co. KGaA / Key word(s): Dividend Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million

December 6, 2023

Check your dad jeans — and genes — in J&J’s new BRCA-focused campaign

Many people are familiar with BRCA, or breast cancer gene 1 and 2, mutations in breast cancer, but they can also play a role in

January 27, 2024

Bluebird tweaks partnership with Lonza to boost Zynteglo, Skysona manufacturing capacity

Bluebird bio is amending its deal with Lonza for the Swiss CDMO to boost the manufacturing capacity of bluebird’s approved gene therapies Zynteglo and Skysona.

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.